Abstract
The constitutive BCR–ABL1 active protein fusion has been identified as the main cause of chronic myeloid leukemia. The emergence of T334I and D381N point mutations in BCR–ABL1 confer drug resistance. Recent experimental studies show a synergistic effect in suppressing this resistance when Nilotinib and Asciminib are co-administered to target both the catalytic and allosteric binding site of BCR–ABL1 oncoprotein, respectively. However, the structural mechanism by which this synergistic effect occurs has not been clearly elucidated. To obtain insight into the observed synergistic effect, molecular dynamics simulations have been employed to investigate the inhibitory mechanism as well as the structural dynamics that characterize this effect. Structural dynamic analyses indicate that the synergistic binding effect results in a more compact and stable protein conformation. In addition, binding free energy calculation suggests a dominant energy effect of nilotinib during co-administration. van der Waals energy interactions were observed to be the main energy component driving this synergistic effect. Furthermore, per-residue energy decomposition analysis identified Glu481, Ser453, Ala452, Tyr454, Phe401, Asp400, Met337, Phe336, Ile334, And Val275 as key residues that contribute largely to the synergistic effect. The findings highlighted in this study provide a molecular understanding of the dynamics and mechanisms that mediate the synergistic inhibition in BCR–ABL1 protein in chronic myeloid leukemia treatment.
Similar content being viewed by others
References
Apperley JF (2015) Chronic myeloid leukaemia. Lancet 385:1447–1459. https://doi.org/10.1016/S0140-6736(13)62120-0
Druker BJ (2001) Current treatment approaches for chronic myelogenous leukemia. Cancer J 7(Suppl 1):S14–S18
Rowley JD (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290
Ren R (2005) Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5:172
Pendergast AM, Quilliam LA, Cripe LD et al (1993) BCR–ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75:175–185
Ben-Neriah Y, Daley GQ, Mes-Masson AM et al (1986) The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233:212–214
Jabbour E, Kantarjian H (2018) Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol 93:442–459
Granatowicz A, Piatek CI, Moschiano E et al (2015) An overview and update of chronic myeloid leukemia for primary care physicians. Korean J Fam Med 36:197–202
Panjarian S, Iacob RE, Chen S et al (2013) Structure and dynamic regulation of Abl kinases. J Biol Chem 288:5443–5450. https://doi.org/10.1074/jbc.R112.438382
Huse M, Kuriyan J (2002) The Conformational Plasticity of Protein Kinases. Cell 109:275–282. https://doi.org/10.1016/S0092-8674(02)00741-9
Nagar B, Bornmann WG, Pellicena P et al (2002) Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62:4236–4243
Schindler T, Bornmann W, Pellicena P et al (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1938–1942
Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9:28–39. https://doi.org/10.1038/nrc2559
Nagar B (2007) c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571). J Nutr 137:1518S–1523S. (discussion 1548S)
Huang X, Cortes J, Kantarjian H (2012) Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118:3123–3127. https://doi.org/10.1002/cncr.26679
Fava C, Morotti A, Dogliotti I et al (2015) Update on emerging treatments for chronic myeloid leukemia. Expert Opin Emerg Drugs 20:183–196
Miura M (2015) Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia. Biol Pharm Bull 38:645–654
Roskoski R Jr (2016) Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol Res 103:26–48
Shah NP, Nicoll JM, Nagar B et al (2002) Multiple BCR–ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117–125
Schoepfer J, Jahnke W, Berellini G et al (2018) Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR–ABL1. J Med Chem 61:8120–8135. https://doi.org/10.1021/acs.jmedchem.8b01040
Wylie AA, Schoepfer J, Jahnke W et al (2017) The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1. Nature 543:733–737. https://doi.org/10.1038/nature21702
Wylie A, Schoepfer J, Berellini G et al (2014) ABL001, a potent allosteric inhibitor of BCR–ABL, prevents emergence of resistant disease when administered in combination with nilotinib in an in vivo murine model of chronic myeloid leukemia. Blood 124:398–398
Eadie LN, Saunders VA, Leclercq TM et al (2015) The allosteric inhibitor ABL001 is susceptible to resistance in vitro mediated by overexpression of the drug efflux transporters ABCB1 and ABCG2. Blood 126:4841–4841
Ottmann OG, Alimena G, DeAngelo DJ et al (2015) ABL001, a potent, allosteric inhibitor of BCR–ABL, exhibits safety and promising single- agent activity in a phase I study of patients with CML with failure of prior TKI therapy. Blood 126:138–138
Hughes TP, Goh Y-T, Ottmann OG et al (2016) Expanded phase 1 Study of ABL001, a potent, allosteric inhibitor of BCR–ABL, reveals significant and durable responses in patients with CML-chronic phase with failure of prior TKI therapy. Blood 128:625–625
Druker BJ, Sawyers CL, Kantarjian H et al (2001) Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. N Engl J Med 344:1038–1042. https://doi.org/10.1056/NEJM200104053441402
Hassan AQ, Sharma SV, Warmuth M (2010) Allosteric inhibition of BCR–ABL. Cell Cycle 9:3734–3738. https://doi.org/10.4161/cc.9.18.13232
Webb B, Sali A (2014) Protein structure modeling with MODELLER. Protein Struct Predict 47:1–15
Pettersen EF, Goddard TD, Huang CC et al (2004) UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 25:1605–1612
Adcock SA, McCammon JA (2006) Molecular dynamics: survey of methods for simulating the activity of proteins. Chem Rev 106:1589–1615. https://doi.org/10.1021/cr040426m
Case DA, Cheatham TE, Darden T et al (2005) The Amber biomolecular simulation programs. J Comput Chem 26:1668–1688. https://doi.org/10.1002/jcc.20290
Burger SK, Schofield J, Ayers PW (2013) Quantum mechanics/molecular mechanics restrained electrostatic potential fitting. J Phys Chem B 117:14960–14966
Sprenger KG, Jaeger VW, Pfaendtner J (2015) The general AMBER force field (GAFF) can accurately predict thermodynamic and transport properties of many ionic liquids. J Phys Chem B 119:5882–5895
Shao Y, Molnar LF, Jung Y et al (2006) Advances in methods and algorithms in a modern quantum chemistry program package. Phys Chem Chem Phys 8:3172–3191
Jorgensen WL, Chandrasekhar J, Madura JD et al (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79:926–935. https://doi.org/10.1063/1.445869
Roe DR, Cheatham TE (2013) PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. J Chem Theory Comput 9:3084–3095
Seifert E (2014) OriginPro 9.1: Scientific data analysis and graphing software—Software review. J Chem Inf Model 54:1552–1552. https://doi.org/10.1021/ci500161d
Ylilauri M, Pentikäinen OT (2013) MMGBSA as a tool to understand the binding affinities of filamin-peptide interactions. J Chem Inf Model 53:2626–2633. https://doi.org/10.1021/ci4002475
Hou T, Wang J, Li Y, Wang W (2011) Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model 51:69–82. https://doi.org/10.1021/ci100275a
Hayes JM, Archontis G (2011) MM-GB (PB) SA calculations of protein-ligand binding free energies. InTech. https://doi.org/10.5772/37107
Pan L, Patterson JC, Deshpande A et al (2013) Molecular dynamics study of Zn(Aβ) and Zn(Aβ)2. PLoS ONE 8:70681–70688. https://doi.org/10.1371/journal.pone.0070681
Wijffels G, Dalrymple B, Kongsuwan K, Dixon N (2005) Conservation of eubacterial replicases. IUBMB Life 57:413–419. https://doi.org/10.1080/15216540500138246
Richmond TJ (1984) Solvent accessible surface area and excluded volume in proteins. Analytical equations for overlapping spheres and implications for the hydrophobic effect. J Mol Biol 178:63–89
Acknowledgements
The authors acknowledge the College of Health Science, the University of KwaZulu-Natal for financial support and Centre of High-Performance Computing (CHPC) Cape Town, RSA, for computational resources (http://www.chpc.ac.za).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
El Rashedy, A.A., Appiah-Kubi, P. & Soliman, M.E.S. A Synergistic Combination Against Chronic Myeloid Leukemia: An Intra-molecular Mechanism of Communication in BCR–ABL1 Resistance. Protein J 38, 142–150 (2019). https://doi.org/10.1007/s10930-019-09820-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10930-019-09820-z